Pharmacokinetics of Apixaban in Nephrotic Syndrome
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Crona, PharmD, PhD
University of North Carolina, Chapel Hill
Principal Investigator - Vimal Derebail, MD, MPH
University of North Carolina, Chapel Hill
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2017
- Primary completion
- 28 Jun 2019
- Completion
- 28 Jun 2019
- Last update posted
- 24 Jul 2019
- Registered enrollment
- 21
- Registry id
- NCT02599532
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.